Approvals In Brief
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genentech’s Lucentis begins shipping June 30 with price set at premium; wholesale acquisition cost is $1,950 per vial. Bristol-Myers Squibb is positioning its second-line leukemia agent Sprycel as a less expensive option than Novartis’ Gleevec following approval June 28; Celgene’s Revlimid clears FDA for treatment of second-line multiple myeloma